Media headlines about Biopharmx Corp (NYSE:BPMX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biopharmx Corp earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.6858787171182 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- Biopharmx Corp (BPMX) Mesa Adaptive MA Sitting Below FAMA - Evergreen Caller (evergreencaller.com)
- From A Very Different Angle: BioPharmX Corporation (BPMX), Synaptics Incorporated (SYNA) - AllStockNews (allstocknews.com)
- 2 Hot Stocks To Watch: BioPharmX (BPMX), Inphi (IPHI) - StockNewsMagazine (stocknewsmagazine.com)
- Analysts Expect Biopharmx Corp (NYSE:BPMX) Will Announce Quarterly Sales of $20,000.00 (americanbankingnews.com)
- BioPharmX Corporation (BPMX) Insider Trading: VIVO CAPITAL FUND VIII, LP bought 1282052 Shares - Economic News (economicsandmoney.com)
Shares of Biopharmx Corp (NYSE:BPMX) traded down 2.7667% on Monday, hitting $0.2917. The company had a trading volume of 888,374 shares. The company has a 50 day moving average price of $0.44 and a 200 day moving average price of $0.51. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $1.22. The firm’s market capitalization is $21.62 million.
Separately, ValuEngine upgraded Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 24th.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/07/biopharmx-corp-nysebpmx-earning-somewhat-positive-media-coverage-report-finds-updated-updated.html.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.
